MDS
MDS
Advertisement
Andrew MorenoASH 2024 | December 20, 2024
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
Read More
Andrew MorenoASH 2024 | December 20, 2024
The study's results especially highlight potential aberrant gene regulation by ZMAT2 and SMARCD3.
Andrew MorenoASH 2024 | December 20, 2024
The study showed a mortality risk reduction benefit in certain mutations while for others larger studies are needed.
Andrew MorenoASH 2024 | December 20, 2024
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Andrew MorenoASH 2024 | December 18, 2024
Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.
Andrew MorenoASH 2024 | December 18, 2024
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
Andrew MorenoASH 2024 | December 18, 2024
Researchers also analyzed baseline stem cells for insight into patient response versus non-response to the combination.
Andrew MorenoASH 2024 | December 18, 2024
The combination was compared with decitabine monotherapy in a multicenter, open-label, RCT.
Patrick DalyASH 2024 | December 16, 2024
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
Andrew MorenoASH 2024 | December 12, 2024
Across several patient subgroups luspatercept was observed to produce longer durations of transfusion independence.
Andrew MorenoASH 2024 | December 11, 2024
Daily oral administration of the agent brought favorable transfusion independence performance and overall safety.
Nichole TuckerASH 2024 | December 8, 2024
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Patrick DalyASH 2024 | December 7, 2024
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Nichole TuckerASH 2024 | December 7, 2024
Luspatercept led to decreases RBCT burden vs epoetin alfa in patients with LR-MDS.
Andrew MorenoASH 2024 | December 7, 2024
A transcriptomic analysis saw CDK8 repression increase expression of myeloid differentiation and oncogenesis genes in HSPCs.
Andrew MorenoASH 2024 | December 7, 2024
In a study, lack of response to the doublet was most prevalent in multi-hit TP53 as compared with wild type or single-hit.
Andrew MorenoMDS | December 6, 2024
The investigators compiled patients' quality of life, social function, and physical scores, and assessed overall survival.
Andrew MorenoMDS | December 6, 2024
The US FDA conferred with experts on ways to improve CMML clinical trials and accelerate treatment advances in this disease.
Andrew MorenoMDS | December 5, 2024
Phase II trial results suggest limits to the IL-1β inhibitor's efficacy by patient genetic complexity and SF3B1 mutation.
Andrew MorenoASH 2024 | December 4, 2024
Rapamycin can normalize erythroid differentiation in SF3B1-mutated MDS by acting upon the mTOR signaling pathway.
Advertisement
Advertisement
Advertisement
Latest News

December 20, 2024